Table 1.
Demographic comparison between HIV+ & HIV− groups
| N = 70 | N = 34 | |
|---|---|---|
| Demographic variable | HIV+ | UCLA HIV− |
| Male sex (%) | 58 (83%) | 17 (50%) |
| Education (years) | 13.32 ± 1.93 | 14.00 ± 2.56 |
| Age | 50.7 ± 11.93 | 53.25 ± 10.28 |
| Age range | 24–76 | 24–66 |
| Ethnicitya | 35% C, 65% AA | 50% C, 50% AA |
| HIV duration | 16.37± 8.13 | |
| Pre‐ HAART diagnosis | 32 (46%) | |
| Nadir CD4 (#/mm3) | 246.1 ± 212. 26 | |
| Current CD4 (#/mm3) | 663.61 ± 282.426 | |
| # (%) with detectable viral load | 8 (11%) | |
| Peak viral load (IU/mL) | 395055.97 ± 767296.72 | |
| (%) with major depression (SCID) | 4 (7%) | 1 (5%) |
| # (%) current barbiturate use (urine screen)b | 24 (34%) | 3 (9%) |
| # (%) current opiate use (urine screen) | 7 (10%) | 1(3%) |
| # (%) current marijuana use (urine screen) | 23 (33%) | 11 (33%) |
| Medical comorbidity burdenb (range/median) | 0–6/1 | 0–3/0 |
| Heart failure | 4 (6%) | 1 (3%) |
| Diabetes | 5 (7%) | 1 (3%) |
| Hypertension | 18 (26%) | 6 (18%) |
| COPD | 4 (6%) | 1 (3%) |
| Kidney disease | 5 (7%) | 0 |
| Anemia | 13 (19%) | 5 (15%) |
| Thyroid condition | 4 (6%) | 1 (3%) |
| Testosterone treatment | 13 (19%) | 2 (6%) |
| Estrogen treatment | 3 (4%) | 1 (3%) |
a
C = Caucasian; AA = African American.
b
p < .05.